Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Avis Budget Group(CAR) Prnewswire·2024-06-28 04:30Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination triggers a $2 million milestone payment to CarismaPHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration ...